Amneal Pharmaceuticals (AMRX -18.6%) inks an agreement with privately held Kashiv BioSciences for exclusive U.S. rights to Phase 2-stage K127 (pyridostigmine) for the treatment of myasthenia gravis, a rare autoimmune disorder characterized by weakness in the skeletal muscles.
Under the terms of the deal, Kashiv will be responsible for all development and clinical work to support a U.S. marketing application while Amneal will file the NDA and commercialize, if approved.
Amneal will pay Kashiv $1.5M upfront, up to $16.5M in milestones and tiered low-double-digit-to-mid-teens royalties on net sales.
Shares are down in reaction to its Q3 report and guidance cut.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.